COLUMBIA BIOTECH IN CANCER DEAL WORTH UP TO $8.4M

A&G Pharmaceutical has entered into an agreement with a South Korean biotech business that could be worth up to $8.4 million plus royalties for the small pharmaceutical company. Columbia-based A&G, which raised a $2 million Series A round of venture capital last September, said Wednesday that it has forged a deal with Incheon, South Korea-based Celltrion for clinical production of a cancer drug now in preclinical development.
Baltimore Business Journal